Company | Leidos Holdings, Inc. | Ticker | LDOS (NYSE) |
Upcoming Earnings Date | August 4, 2026 | Reporting Period | Q2 2026 (2QFY-2026, ending June 30, 2026) |
Last Earnings Date | May 5, 2026 (Q1 2026) | Prepared Date | August 3, 2026 |
Sector | Defense & Government IT Services | Sector ETF | ITA (iShares U.S. Aerospace & Defense ETF) |
Key Takeaway: The setup is mixed-to-cautious — management explicitly guided Q2 as the low point of the year for both revenue growth and margins, making the bar achievable but the optics challenging; the single biggest swing factor is whether the back-half acceleration thesis holds and whether book-to-bill rebounds above 1.0x.
Heading into the Q2 2026 print, consensus expects revenue of ~$4.44B and operating EPS of ~$2.91, both representing modest year-over-year growth against a period where management pre-signaled softness. The bar is intentionally low: on the Q1 call, management explicitly framed Q2 as the trough, citing a Q1 revenue pull-forward, the absence of a one-time insurance reimbursement benefit, and elevated near-term growth investments — meaning a beat is achievable but the magnitude of any upside is likely constrained. Guidance tone remains constructive on the full year ($18.0–$18.4B revenue, $12.10–$12.50 non-GAAP EPS), and estimates have been essentially stable since the Q1 raise, suggesting the Street has already absorbed the ENTRUST acquisition contribution and is not pricing in incremental upside. The stock has been a dramatic underperformer since the Q1 print — down ~13.5% vs. ITA +14.3% and SPY +4.7% — driven by sector rotation into pure-play defense hardware names and investor skepticism about the elevated CapEx cycle and the SES security detection JV overhang; the multiple has compressed meaningfully, which paradoxically creates a lower-risk entry if Q2 confirms the trough narrative. The key wildcard is book-to-bill: a Q1 ratio of only 0.8x (TTM 1.1x) raised questions about award momentum, and a Q2 reading above 1.0x — supported by management's expectation that awards pick up significantly in the second half — would be the single most important signal for the stock's re-rating.
Key Takeaway: Consensus sets a low bar for Q2 given management's explicit trough guidance; revenue is the bigger swing factor given the Q1 pull-forward dynamic, while adjusted EBITDA margin will be watched closely for signs of the investment spend peak management described.
KPI | Q1 2026 Actual (Last Quarter) | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Estimate | YoY Change | FY 2026 Guidance | Consensus vs. Guidance Midpoint |
Revenue ($B) | $4.40B | $4.25B | $4.44B | +4.5% YoY | $18.0B–$18.4B ($18.2B mid) | ~+1.3% above Q2 run-rate implied by midpoint |
Adj. Operating EPS ($) | $3.13 | $3.21 | $2.91 | -9.3% YoY | $12.10–$12.50 ($12.30 mid) | Tracking ~$2.91 vs. implied ~$3.00 quarterly avg; below pace |
Adj. EBITDA ($M) | $614M | $647M | $598M | -7.6% YoY | Mid-13s adj. EBITDA margin | ~13.5% implied; consensus at ~13.5% — in line |
Book-to-Bill (x) | 0.80x (TTM: 1.1x) | 0.94x | ~1.02x (consensus) | +0.08x YoY | No formal guidance; mgmt expects awards to pick up significantly H2 | N/A — no formal guidance |
Funded Backlog ($B) | $9.60B | $7.12B | $9.65B | +35.5% YoY | No formal guidance | N/A — no formal guidance |
Free Cash Flow ($M) | $270M | $457M | $336M | -26.5% YoY | ~$1.8B FY 2026 operating cash flow | FY consensus $1.52B FCF vs. ~$1.8B OCF guidance — CapEx drag |
Source: Visible Alpha consensus and actuals data. Q2 2026 consensus as of August 3, 2026. All VA-sourced figures cited per Visible Alpha Consensus and Actuals Data.
Quarter | Reported ($B) | Consensus ($B) | Surprise % | Result |
Q2 2024 | $4.13B | $4.06B | +1.7% | Beat |
Q3 2024 | $4.19B | $4.07B | +2.9% | Beat |
Q4 2024 | $4.37B | $4.13B | +5.7% | Beat |
Q1 2025 | $4.25B | $4.10B | +3.7% | Beat |
Q2 2025 | $4.25B | $4.25B | 0.0% | In Line |
Q3 2025 | $4.47B | $4.28B | +4.4% | Beat |
Q4 2025 | $4.21B | $4.31B | -2.4% | Miss |
Q1 2026 | $4.40B | $4.28B | +2.8% | Beat |
Quarter | Reported ($) | Consensus ($) | Surprise % | Result |
Q2 2024 | $2.63 | $2.26 | +16.4% | Beat |
Q3 2024 | $2.93 | $2.01 | +45.8% | Beat |
Q4 2024 | $2.37 | $2.24 | +5.8% | Beat |
Q1 2025 | $2.97 | $2.48 | +19.8% | Beat |
Q2 2025 | $3.21 | $2.66 | +20.7% | Beat |
Q3 2025 | $3.05 | $2.74 | +11.3% | Beat |
Q4 2025 | $2.76 | $2.60 | +6.2% | Beat |
Q1 2026 | $3.13 | $2.90 | +7.9% | Beat |
Pattern: LDOS has beaten EPS consensus in all 8 of the last 8 quarters, with an average beat of ~17% — a remarkably consistent track record. Revenue beats are also the norm (6 of 8 quarters), with the only miss in Q4 2025 driven by a seasonal step-down. The EPS beat pattern reflects structural margin outperformance vs. Street models; however, the magnitude of beats has been compressing as the Street has caught up, and Q2 2026 consensus already embeds the management-guided trough, making a large upside surprise harder to achieve.
Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: Guidance was raised across all metrics at Q1 2026 earnings (May 5, 2026) primarily to incorporate the ENTRUST acquisition; no post-earnings guidance revisions have been issued since. Management tone is constructive on the full year but explicitly cautious on Q2, framing it as a deliberate investment trough before a second-half step-up.
Metric | Initial Guidance (Q4 2025 Earnings, Feb 17, 2026) | Revised Guidance | Current Consensus | Note |
FY 2026 Revenue | $17.5B–$17.9B (excl. ENTRUST) | $18.0B–$18.4B | $18.26B | ↑ Raised at Q1 2026 earnings (May 5, 2026); +$500M increase primarily reflects ENTRUST acquisition contribution; integration ahead of schedule |
FY 2026 Adj. EBITDA Margin | Mid-13s | — (Unchanged) | ~13.6% implied by consensus | Maintained at Q1 2026 earnings; management confident margins sustainable despite elevated CapEx investment cycle |
FY 2026 Non-GAAP Diluted EPS | $12.05–$12.45 | $12.10–$12.50 | $12.31 | ↑ Raised +$0.05 at Q1 2026 earnings (May 5, 2026); ENTRUST accretive to non-GAAP EPS in 2026 (faster than expected) |
FY 2026 Operating Cash Flow | ~$1.75B | ~$1.80B | ~$1.52B FCF (consensus) | ↑ Raised +$50M at Q1 2026 earnings; FCF below OCF guidance due to tripled CapEx ($350M budgeted, though actual spend TBD based on program ramp) |
FY 2026 CapEx | ~$350M (3x prior year) | — (Unchanged target; actual TBD) | N/A — not tracked in VA | Q1 actual CapEx only $31M; management noted full $350M may not be spent depending on program layering; purposeful peak, not permanent step-up |
Q2 2026 Revenue / Margin | Not guided at Q4 2025 call | Guided as “likely low point” at Q1 2026 call | $4.44B revenue; ~13.5% adj. EBITDA margin | Management cited Q1 pull-forward, absence of insurance reimbursement, and rising near-term growth investments as Q2 headwinds; H2 step-up expected |
Key Takeaway: Estimates for Q2 2026 and FY 2026 have been essentially stable since the Q1 earnings raise, with only marginal drift; the Street is tracking guidance closely and not pricing in incremental upside, which means the risk/reward is more balanced than the stock's underperformance implies.
KPI (Period) | Estimate ~5 Days Post Q1 Earnings (May 12, 2026) | Current Consensus (Aug 3, 2026) | Estimate Δ (%) | Initial Guidance (Q4 2025 Call, Feb 17) | Current Guidance (Q1 2026 Call, May 5) | Guidance Δ | Consensus vs. Current Guidance Midpoint |
Revenue — Q2 2026 | $4.43B | $4.44B | +0.3% | N/A (no Q2 guidance) | N/A (no Q2 guidance) | N/A | N/A |
Revenue — FY 2026 | $18.26B | $18.26B | 0.0% | $17.5B–$17.9B | $18.0B–$18.4B | +$500M midpoint | +0.3% above $18.2B midpoint |
Revenue — FY 2027 | $19.21B | $19.11B | -0.5% | No formal guidance | No formal guidance | N/A | N/A |
Adj. Operating EPS — Q2 2026 | $2.86 | $2.91 | +1.7% | N/A (no Q2 guidance) | N/A (no Q2 guidance) | N/A | N/A |
Adj. Operating EPS — FY 2026 | $12.33 | $12.31 | -0.1% | $12.05–$12.45 | $12.10–$12.50 | +$0.05 midpoint | +0.1% above $12.30 midpoint |
Adj. Operating EPS — FY 2027 | $13.17 | $13.14 | -0.2% | No formal guidance | No formal guidance | N/A | N/A |
Adj. EBITDA — Q2 2026 | $592M | $598M | +1.0% | N/A (no Q2 guidance) | N/A (no Q2 guidance) | N/A | N/A |
Adj. EBITDA — FY 2026 | $2.496B | $2.490B | -0.3% | Mid-13s margin | Mid-13s margin (maintained) | Unchanged | ~13.6% implied; in line with guidance |
Estimates have been remarkably stable since the Q1 2026 raise — essentially flat across revenue, EPS, and EBITDA for both Q2 and the full year. This tells two stories: (1) the Street has fully digested the ENTRUST contribution and is not modeling incremental upside, and (2) there is no estimate risk to the downside either, as the trough was pre-signaled. The FY 2027 estimates have drifted marginally lower (-0.2% to -0.5%), suggesting some caution about the back-half acceleration thesis extending into next year.
Source: Visible Alpha Consensus and Actuals Data. Post-earnings baseline as of May 12, 2026 (5 trading days after Q1 2026 earnings on May 5, 2026).
Key Takeaway: LDOS has dramatically underperformed since Q1 earnings — down ~13.5% vs. ITA +14.3% and SPY +4.7% — driven by multiple compression and sector rotation into pure-play defense hardware names, not by estimate cuts; the stock's de-rating creates a lower-risk setup heading into Q2 if management confirms the trough narrative.
LDOS vs. ITA (iShares U.S. Aerospace & Defense ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (May 5, 2026). Source: Stock Price Data.
LDOS opened the post-earnings period with an immediate ~8% gap down on May 5, 2026, as investors focused on the Q2 trough guidance and the Q1 pull-forward framing rather than the headline beat. The stock continued to drift lower through June, reaching a trough of ~$100 (indexed) in late June, as the defense sector rotated sharply into hardware/product names (ITA +14% over the same period) while LDOS — perceived as more services-oriented despite its growing product mix — was left behind. A partial recovery in late July/early August (stock recovering to ~$118 by Aug 4) coincided with BAH's Q1 FY2027 earnings (July 24) showing improving funding trends and a 1.5x book-to-bill, which served as a positive read-through for the sector. The ITA ETF is the appropriate sector benchmark for LDOS given its defense and government technology exposure. No analyst rating changes were recorded in the period.
Key Takeaway: Peer commentary from CACI, SAIC, and BAH over the last 60 days paints a picture of a gradually improving but uneven demand environment — funding is recovering, award activity is picking up from shutdown lows, and book-to-bill is rebounding — all of which are directionally positive read-throughs for LDOS's Q2 and H2 2026 outlook. The key risk flagged across peers is near-term award delays as the government transitions to fixed-price procurement.
Note: Only commentary from the last 60 days (since ~June 4, 2026) that speaks to the current Q2 2026 reporting period or the forward demand environment is included below. Prior-quarter earnings commentary about prior-quarter results is excluded.
Relevance to LDOS: BAH is LDOS's closest peer in national security IT and defense technology. BAH's Q1 FY2027 covers the same calendar quarter as LDOS's Q2 2026 (April–June 2026), making this the most direct read-through available.
Relevance to LDOS: CACI is a direct peer in national security IT and defense technology. Conference commentary in June 2026 speaks directly to the Q2 2026 demand environment.
Relevance to LDOS: Conference commentary from May 12, 2026 (one week post-LDOS Q1 earnings) provides early read on Q2 2026 demand conditions.
Relevance to LDOS: SAIC is a direct peer in government IT services. SAIC's fiscal Q1 FY2027 (ending May 1, 2026) covers the early part of LDOS's Q2 2026 period and provides a read on the demand environment entering the quarter.
Overall Read-Through Summary: The peer mosaic is constructive for LDOS's Q2 print and H2 outlook. Funding is recovering (BAH +17-18% YoY), book-to-bill is rebounding (BAH 1.5x, SAIC 1.1x), and the award pipeline is building toward a bow wave (CACI $22B in 180-day submissions). The primary risk is near-term award delays from fixed-price procurement reform and midterm election-year budget uncertainty — both of which management has already flagged. The peer data supports the trough narrative and makes a Q2 beat on book-to-bill the most likely positive catalyst.
Key Takeaway: The most important development since Q1 earnings is the SES security detection JV with Analogic (Altaris) — a portfolio rationalization that removes a non-core business from consolidated revenue but retains upside through a minority stake; the Q2 print will be the first to reflect the JV's accounting treatment if it has closed.
Key Takeaway: The only open-market sale in the period was a discretionary sale by Director Gary Stephen May on May 7, 2026 (two days post-earnings), involving 1,484 shares (~$194K) — modest in size and not a meaningful signal. All other activity consists of routine equity award grants (code A) and tax withholding dispositions (code F) associated with vesting events; no open-market purchases were recorded.
Name | Title | Transaction Type | Shares | Est. Value | Transaction Date | Note |
May, Gary Stephen | Director | Open Market Sale (Code S) | 1,484 | ~$194K | May 7, 2026 | Discretionary sale; 2 days post-Q1 earnings; modest size relative to 10,137 shares held; not on 10b5-1 plan |
May, Gary Stephen | Director | Option Exercise (Code M) | 3,345 | N/A | May 7, 2026 | Exercise of stock options; associated with the same-day sale above; routine exercise-and-sell pattern |
May, Gary Stephen | Director | Tax Withholding (Code F) | 1,861 | N/A | May 7, 2026 | Shares withheld for tax obligation on option exercise; not a discretionary sale |
Bell, Thomas Arthur | CEO, Director | Tax Withholding (Code F) | 2,530 | N/A | May 5, 2026 | Shares withheld for tax on vesting event (earnings day); routine; not a discretionary sale; CEO retains 108,696 shares |
Antal, Daniel J. | EVP, General Counsel | Tax Withholding (Code F) | 188 (direct) + 18 (indirect) | N/A | May 3, 2026 | Routine tax withholding on vesting; not discretionary |
Multiple Directors (8 individuals) | Board of Directors | Annual Equity Grant (Code A) | 1,067 shares + 1,281 options each | N/A | May 8, 2026 | Routine annual director equity compensation grants; no discretionary signal |
Cage, Christopher R. | CFO | Equity Grant (Code A, Deferral Plan) | 113.2 (deferred) | N/A | June 30, 2026 | Routine deferred compensation plan accrual; not a discretionary transaction |
The insider picture is benign. The only open-market sale — Director Gary May's 1,484-share sale on May 7 — was part of a routine option exercise-and-sell transaction and is not a meaningful negative signal given its small size (~$194K vs. a $108K+ CEO share position). Notably, CEO Thomas Bell's only transaction was a tax withholding on earnings day (not a discretionary sale), and the CFO's activity was limited to routine deferred compensation plan accruals. There are no clustered open-market buys or unusual sale patterns. The absence of any open-market purchases is not alarming given the stock's post-earnings decline, but it is also not a positive signal.
Source: SEC Form 4 Filings Database (Insider Transaction Data). Transactions cover May 1, 2026 – August 3, 2026.